IgD型复发难治多发性骨髓瘤患者BCMA靶点再治疗1例报告并文献复习 Article Swipe

View

Related Concepts

Chimeric antigen receptor Immunoglobulin D Refractory (planetary science) Medicine Immunology Multiple myeloma Cancer research Immunotherapy Antibody Biology B cell Immune system Astrobiology

Siyu Gu , Wanting Qiang , Jin Lu , Feng Zhao , Juan Du ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.3760/cma.j.cn121090-20240426-00165 · OA: W4405028577

Multiple myeloma（MM）is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen（BCMA）have greatly improved the efficacy and prognosis of MM compared with traditional treatments. This article reports the case of an IgD type relapsed and refractory MM patient with poor efficacy of BCMA×CD3 bispecific antibody. The patient achieved deep remission after receiving BCMA-targeted CAR-T cell therapy after initial seven lines of treatment. Literature review was also conducted to improve the clinical physicians' understanding of BCMA target therapy for relapsed and refractory MM patients.